Impact on weight and height with the use of HAART in HIV-infected children

Pediatric Infectious Disease Journal

Volumn 26, Issue 4, 2007, Pages 334-338

  Guillén, Sara ^a   Ramos, José Tomás ^a,b   Resino, Rosa ^c   Bellón, José María ^c   Muñoz, María Angeles ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Children; Growth; HAART; HIV infection

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; CHILD GROWTH; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFANT; LIPOATROPHY; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; TREATMENT OUTCOME;

EID: 34247121800     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000257427.19764.ff     Document Type: Article

References (13)

1. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003;327:1019.
2. Resino S, Bellón J, Resino R, et al. Extensive implementation of highly active antiretroviral therapy shows great effectiveness on the survival and surrogate markers in vertically HIV-infected children. Clin Infect Dis. 2004;38:1605-1612.
3. Sanchez JM, Ramos Amador JT, Fernandez de Miguel S, et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003;22:863-867.
4. Nachman SA, Lindsey JC, Moye J, et al. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J. 2005;24:352-357.
5. Hankin C, Thorne C, Newell ML. Does exposure to antiretroviral therapy affect growth in the first 18 months of life in uninfected children born to HIV-infected women? J Acquir Immune Defic Syndr. 2005;40:364-370.
6. Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics. 2002;109:E25.
7. CDC. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR CDC Surveill. 1994;43:1-10.
8. Steiner F, Kind C, Aebi C, et al. Growth in human immunodeficiency virus type 1-infected children treated with protease inhibitors. Eur J Pediatr. 2001;160:611-616.
9. Dreimane D, Nielsen K, Deveikis A, Bryson YJ, Geffner ME. Effect of protease inhibitors combined with standard antiretroviral therapy on linear growth and weight gain in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J. 2001;20:315-316.
10. Buchacz K, Cervia JS, Lindsey JC, et al. Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics. 2001;108:E72.
11. Miller TL, Mawn BE, Orav EJ, et al. The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children. Pediatrics. 2001;107:E77.
12. Doerholt K, Walker S, Sharland M, et al. Long-term growth in previously untreated HIV infected children starting HAART in the Collaborative HIV Paediatric Study (CHIPS) the UK and Ireland. Paper presented at: AIDS Conference; Julio 2004; Bangkok, Abstract ThuPeB4424.
13. Van Rossum AM, Gaakeer MI, Verweel S, et al. Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors. Pediatr Infect Dis J. 2003;22:70-76.